InventisBio (SH:688382) Sou Hu Cai Jing·2025-08-23 00:16Group 1 - Yifang Bio (688382.SH) reported its semi-annual results for 2025, with 142 institutional investors holding a total of 351 million shares, representing 60.69% of the company's total equity as of August 22, 2025 [1] - The top ten institutional investors collectively hold 41.89% of Yifang Bio's shares, with a decrease of 1.73 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 14 funds increased their holdings, with a total increase ratio of 1.17%, including notable funds such as Changcheng Medical Industry Selected Mixed Fund and China Europe Medical Health Mixed Fund [2] - Conversely, 24 public funds reduced their holdings, with a decrease ratio of 0.94%, including funds like Penghua Medical Technology Stock A and Changsheng Tongde Theme Mixed Fund [2] - A total of 93 new public funds were disclosed this period, including funds like Huatai PineBridge Innovation Medical Mixed A and Ping An Medical Health Mixed A [2] - Ten public funds were not disclosed this period, including funds like Rongtong Medical Health Industry Mixed A/B and China Universal Industry Advantage Mixed A [2] Group 3 - In terms of foreign investment, three foreign funds reduced their holdings, with a decrease ratio of 2.40%, including ABA-Bio (Hong Kong) Limited and LAV Apex Hong Kong Limited [3] - One foreign institution, LAV Alpha Hong Kong Limited, was not disclosed this period [3]